Alnylam Pharmaceuticals is a biopharmaceutical company that focuses on the development of RNA interference (RNAi) therapeutics. The company is dedicated to translating the Nobel Prize-winning discovery of RNAi into a new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options.

Alnylam is committed to sustainability and has taken steps to integrate environmental, social, and governance (ESG) considerations into its business operations. The company aims to minimize its environmental impact through various initiatives, although specific details on carbon footprint calculations or sustainability certifications are not extensively documented.

Alnylam's sustainability efforts include reducing waste, conserving energy, and promoting a culture of responsibility among its employees. The company also emphasizes ethical business practices and strives to maintain transparency in its operations.

While Alnylam Pharmaceuticals is making strides in sustainability, there is limited publicly available information on comprehensive ESG reports or specific sustainability accreditations. The company continues to work towards enhancing its sustainability practices as part of its broader commitment to corporate responsibility.